Psychiatr. praxi. 2025;26(1):55-62

Farmakoterapie schizofrenie při komorbidním abúzu. Využití kariprazinu v klinické praxi

MUDr. Zuzana Zafarová

Zpracováno na základě přednášek MUDr. Martina Hýži, Ph.D. a MUDr. Mgr. Barbory Kohútové, Ph.D.
Farmakoterapii při komorbidním abúzu bylo věnováno sympozium společnosti Richter Gedeon na 67. česko-slovenské psychofarmakologické konferenci, které proběhlo 17. ledna 2025 v Mariánských Lázních.

Published: April 10, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Farmakoterapie schizofrenie při komorbidním abúzu. Využití kariprazinu v klinické praxi. Psychiatr. praxi. 2025;26(1):55-62.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Khokhar JY, Dwiel LL, Henricks AM, et al. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res. 2018 Apr;194:78-85. Go to original source... Go to PubMed...
    2. Alsuhaibani R, Smith DC, Lowrie R, et al. Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. 2021 Apr 23;21(1):209. Go to original source... Go to PubMed...
    3. Hernández-Huerta D, Morillo-González J. Dopamine D3 partial agonists in the treatment of psychosis and substance use disorder comorbidity: a pharmacological alternative to consider? CNS Spectr. 2021 Oct;26(5):444-445. Go to original source... Go to PubMed...
    4. Ward HB, et al. Substance use disorders in schizophrenia: Prevalence, etiology, biomarkers, and treatment. Pers. Med. July-August 2023;39-40:100106. Go to original source...
    5. Nathan R, Lewis E. Assessment of coexisting psychosis and substance misuse: complexities, challenges and causality. BJPsych Advances. Jan 2021;(1)27:38-48. Go to original source...
    6. Souza DC, DiForti M, Ganesh S, et al. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World J Biol Psychiatry. 2022 Dec;23(10):719-742. Go to original source... Go to PubMed...
    7. Alsuhaibani R, Smith DC, Lowrie R, et al. Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. 2021 Apr 23;21(1):209. Go to original source... Go to PubMed...
    8. Starzer MSK, Hansen HG, Hjorthøj C, et al. Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial. Schizophr Bull. 2023 Sep 7;49(5):1256-1268. Go to original source... Go to PubMed...
    9. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013 Sep; 67(6):367-383. Go to original source... Go to PubMed...
    10. Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. Am J Psychiatry. 2019 Sep 1;176(9):711-719. Go to original source... Go to PubMed...
    11. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. Am J Psychiatry. 2018 Apr 1;175(4):343-350. Go to original source... Go to PubMed...
    12. Levi L, Bar-Haim M, Winter-van Rossum I, et al. Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. Schizophr Bull. 2023 Jul 4; 49(4):903-913. Go to original source... Go to PubMed...
    13. Schoeler T, Petros N, Di Forti M, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry. 2016 Oct;3(10):947-953. Go to original source... Go to PubMed...
    14. Agid, et al. Neuropsychopharmacology. 2014;39:S373-S374
    15. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021. Go to original source...
    16. Boileau I, Payer D, Houle S, et al. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci. 2012 Jan 25;32(4):1353-1359. Go to original source... Go to PubMed...
    17. Zhan J, Jordan CJ, Bi GH, et al. Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice. Neuropharmacology. 2018 Oct;141:11-20. Go to original source... Go to PubMed...
    18. Martinotti G, Chiappini S, Mosca A, et al. Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Curr Pharm Des. 2022;28(27):2241-2259. Go to original source... Go to PubMed...
    19. Galaj E, Newman AH, Xi ZX. Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges. Neurosci Biobehav Rev. 2020 Jul;114:38-52. Go to original source... Go to PubMed...
    20. Grunze H. The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):1985-1992. Go to original source... Go to PubMed...
    21. Machielsen M, Beduin AS, Dekker N, et al; Genetic Risk and Outcome of Psychosis (GROUP) investigators. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol. 2012 Jan;26(1):189-195. Go to original source... Go to PubMed...
    22. Martinotti G, Chiappini S, Mosca A, et al. Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Curr Pharm Des. 2022;28(27):2241-2259. Go to original source... Go to PubMed...
    23. Martinez-Raga J, Bajouco M, Kenzin D, et al. Dual disorder: does expert clinical experience support the rationale for cariprazine use? Eur Rev Med Pharmacol Sci. 2024 Mar; 28(5):2095-2106.
    24. Masopust J, Mohr P, Kopeček M. Antipsychotika v léčbě predominantních negativních příznaků schizofrenie: aktualizace doporučených postupů. Psychiatrie. 2020; 24(1):40-45.
    25. Szerman N, Vega P, Roncero C, et al. Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. Int Clin Psychopharmacol. 2024 Sep 25. Go to original source... Go to PubMed...
    26. Phahladira L, Luckhoff HK, Asmal L, et al. Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. NPJ Schizophr. 2020 Jan 8;6(1):2. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.